[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553606":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":30,"locations":39,"responsibleParty":77,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":20,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":20,"maxAge":91,"enrollmentInfo":92,"targetDuration":20,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":62,"whyStopped":20,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"United Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Test formula","EXPERIMENTAL","The test product is a thickened infant formula containing symbiotic (fibers and probiotics)",[13],"Dietary Supplement: New infant formula",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIETARY_SUPPLEMENT","New infant formula","The new formula will be given to infants during the 4-month study period.",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Christophe Batard, Dr.","Ambulatory pediatrician in Vincennes (France)","STUDY_DIRECTOR",{"name":27,"affiliation":28,"role":29},"Camille Jung, Prof.","Centre Hospitalier Intercommunal (CHI) in Créteil (France)","STUDY_CHAIR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":20,"email":35},"Anne-Sophie Garreau","CONTACT","0033-155372222","as.garreau@novalac.com",{"name":37,"role":33,"phone":34,"phoneExt":20,"email":38},"Caroline Thevret, Dr.","c.thevret@novalac.com",[40,52,60,69],{"facility":41,"status":42,"city":43,"state":20,"zip":20,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":20},"Site 02","NOT_YET_RECRUITING","Nice","France","FR",{"type":47,"coordinates":48},"Point",[49,50],7.26608,43.70313,{"lat":50,"lon":49},{"facility":53,"status":42,"city":54,"state":20,"zip":20,"country":44,"countryCode":45,"cosmosGeoPoint":55,"geoPoint":59,"contacts":20},"Site 04","Paris",{"type":47,"coordinates":56},[57,58],2.3488,48.85341,{"lat":58,"lon":57},{"facility":61,"status":62,"city":63,"state":20,"zip":20,"country":44,"countryCode":45,"cosmosGeoPoint":64,"geoPoint":68,"contacts":20},"Site 03","RECRUITING","Toulon",{"type":47,"coordinates":65},[66,67],5.92836,43.12442,{"lat":67,"lon":66},{"facility":70,"status":62,"city":71,"state":20,"zip":20,"country":44,"countryCode":45,"cosmosGeoPoint":72,"geoPoint":76,"contacts":20},"Site 01","Vincennes",{"type":47,"coordinates":73},[74,75],2.43769,48.8486,{"lat":75,"lon":74},{"type":78,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[80],{"name":81,"class":82},"Axiodis CRO","UNKNOWN","100553606","evolution-of-functional-gastrointestinal-disorders-in-infants-fed-with-a-new-infant-formula-100553606",false,"NCT06488274","Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula","Assessment of the Evolution of functIonal Gastrointestinal Disorders in Infants During Their Dietary Management With a New Infant Formula","Inclusion Criteria:\n\n1. Infants presenting with at least one of the FGIDs below, defined based on adapted Rome IV criteria as follows:\n\n   1.1 Regurgitations: 1.2 Colic: 1.3 Constipation:\n2. Infants born at 35 weeks or more of gestational age\n3. Infants up to 4 months of age\n\nExclusion Criteria:\n\n1. Exclusively or partially breastfed infants (i.e. \\> 2 breast feeds per day) with maternal willingness to continue breastfeeding\n2. Diversified infants or whose parents intend to start diversification within the first 2 weeks of the study\n3. Use of antibiotics at inclusion visit (V0) and within 7 days before the inclusion visit (V0)\n4. The willingness to take additional pre-, probiotics or thickening agents during the study\n5. Known allergy\u002Fintolerance to any of the product ingredients or suspected allergy to cow's milk requiring an eviction diet\n6. Infants presenting with any other situation including the participation in another clinical trial, which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the patient\n\n(non exhaustive list)","ALL","4 Months",{"count":93,"type":94},139,"ESTIMATED","INTERVENTIONAL",[97],"NA","This study aims to assess the evolution of functional gastrointestinal disorders (FGIDs) in infants fed with a new infant formula, using the Gastrointestinal (GI) and gastroesophageal reflux (GER) (GIGER) scale through an interventional, open-label, non-comparative multicenter study.",[100],"Functional Gastrointestinal Disorders",[102,103,104,105,106,107,108],"Regurgitations","Colic","Constipation","Infant formula","GIGER scale","Nutrition","Infants","2025-01-02",{"date":111,"type":112},"2025-01-06","ACTUAL",{"date":114,"type":112},"2024-10-21",{"date":116,"type":94},"2026-04",{"name":5,"class":6},4]